Familial Mediterranean Fever (FMF) is the most frequent periodic febrile syndrome among the autoinflammatory syndromes (AS), nowadays considered as innate immunity disorders, characterized by absence of autoantibodies and autoreactive T lymphocytes.
FMF is a hereditary autosomal recessive disorder, characterized by recurrent, self-limiting episodes of short duration (mean 24e72 h) of fever and serositis. In FMF, periodic attacks show inter- and intra-individual variability in terms of frequency and severity. Usually, they are triggered by apparently innocuous stimuli and may be preceded by a prodromal period. The Mediterranean FeVer gene (MEFV) responsible gene maps on chromosome 16 (16p13) encoding the Pyrine/Marenostrin protein. The precise pathologic mechanism is still to be definitively elucidated; however a new macromolecular complex, called inflammasome, seems to play a major role in the control of inflammation and it might be involved in the pathogenesis of FMF.
The most severe long-term complication is type AA amyloidosis, causing chronic renal failure. Two types of risk factors, genetic and non-genetic, have been identified for this complication.
Currently, the only effective treatment of FMF is the colchicine. New drugs in a few colchicine resistant patients are under evaluation.
Corresponding Author: Raffaele Manna, MD; e-mail: email@example.comFree PDF Download
To cite this article
R. Manna, C. Cerquaglia, V. Curigliano, C. Fonnesu, M. Giovinale, E. Verrecchia, M. Montalto, G. de Socio, A. Soriano, M. La Regina, G. Gasbarrini
Clinical features of familial mediterranean fever: an italian overview
Eur Rev Med Pharmacol Sci
Vol. 13 - N. 1 Suppl